- Study type: Randomised Clinical Trial, Treatment
- Study type descriptors: Randomised controlled trial, Multicentre
- Objective: To evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized at baseline with mild-to-moderate COVID-19
- Number of participants enrolled: Enrollment ongoing
- Study enrolling from to
- Study includes follow-up for 24 weeks
Study Data
- Adults (18-64 years)
- Elderly (≥65 years)
- Immunocompromised patients
- Hospital
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Ibuzatrelvir
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to